Esketamine (Spravato)

FDA announces approval of Esketamine (Spravato) for depression

Read about Barbara, one of our many treatment successes, featured in the current edition of TIME Magazine “New Hope for Depression”

TMS Lecture

Visit our image gallery.

News

  •  January  7, 2019: “Harebrained Approach to Treating Depression with a Horse Tranquilizer Turns Ten Years Old”   Article commemorates the tenth anniversary of Dr. Feifel’s historic establishment of the first ketamine for depression infusion program while he was on faculty as a professor of psychiatry at UC San Diego. https://www.finance.yahoo.com/news/harebrained-approach-treating-depression-horse-112500872.html
  • August 22, 2018:   FDA clears deep TMS  for O.C.D. and Kadima is among the first to provide this treatment.       https://www.biospace.com/article/releases/kadima-neuropsychiatry-institute-among-first-centers-to-provide-novel-ocd-treatment-recently-approved-by-the-fda/
  • June 23, 2018:  Article on new finding about Ketamine’s potential action in the brain cites Dr. Feifel  “David Feifel, one of the pioneers in using ketamine to treat depression, says the study suggests that blocking N-methyl-D-aspartate (NMDA for short) receptors may not be the important action of Ketamine when it comes to its antidepressant effect.” Read full story including Dr. Feifel’s  full analysis of the new study here:   https://www.inverse.com/article/46327-ketamine-used-for-depression
  • June 13, 2018:    An Article in Chemical & Engineering News describes a new study showing ketamine has the ability to rapidly grow connections between brain cells and shares this property with other ‘psychedelic’ drugs showing promise for  as treatments for, depression, anxiety, PTSD and other  psychiatric conditions. The article solicited Dr. Feifel’s opinion on the new findings: “David Feifel, a professor emeritus of psychiatry at University of California, San Diego, who has used ketamine to treat patients with depression, says more work is needed before the reported mechanisms can be identified as those responsible for these drugs’ antidepressant properties. The next step, he says, would be to block the pathway outlined in this study and then see if that prevents the drugs from producing an antidepressant effect in animals.  https://cen.acs.org/biological-chemistry/neuroscience/Psychedelics-forge-connections-between-neurons/96/i25
  • May 10, 2018:  An article published in Wired Magazine about Ketamine as a treatment for depression (“Ketamine stirs up hope controversy as a depression-drug”)  describes an interview with one of Dr. Feifel’s patients.  Here is an excerpt: “In middle age, he became so despondent that he decided to end his life. He sent what he thought would be one of his final emails, to a ketamine clinic he’d heard about run by a psychiatrist named David Feifel. Feifel agreed to see him and during his first session the man had a vision, ….he told me in a phone call, weeping… “I felt like I was finally reconnected to the source of life.”  
  • April, 2018: Dr. Feifel is re-elected to serve another term on the Board of  The Clinical TMS Society by the organizations 300+ members. Dr. Feifel is also re-appointed by the Board to co-chair, with Harvard neurologist, professor Daniel Press,  the organization’s Clinical Standards Committee, whose mandate is to set the practice standards for TMS therapy.
  • March 21-23 , 2018: The first international conference on Ketamine and Related Compound for Psychiatric Disorders will take place at Oxford University “where the world’s leading will speak on cutting-edge clinical research and practice” Dr. Feifel has been invited to present results of his clinical work with ketamine and his research on the safety of long term treatment of depression with ketamine.
  • February 15, 2018: Invited to give a lecture on the use of Ketamine for psychiatric disorders at the largest annual neuropharmacology update conference in the U.S., Dr. Feifel addresses 1500 mental health providers in Las Vegas
  • August 2017: The cover story of TIME Magazine details the remarkable advances in treating depression such as low-dose ketamine and TMS. Dr Feifel is consulted by the editor of the story which features an interview with one of Dr. Feifel’s patient’s and photo of a treatment at Kadima.
  • October 2017: The first scientific paper describing the effectiveness and safety of treating treatment resistant depression with sub-anesthetic doses of ketamine in a “real world” context (i.e. not a clinical trial) is published by Dr. Feifel and colleagues
  • March 2017: Dr. Feifel leaves UCSD after 20 years to open Kadima Neuropsychiatry Institute
  • March 2017: American Psychiatric Association publishes guidelines on ketamine treatment for depression
  • February 2009: Dr Feifel becomes the first provider in San Diego to offer FDA cleared TMS treatment with Neurostar system
  • October 2008:  FDA clears the first TMS system:  Neurostar TMS system by Neuronetics